Dosing of LT4 in Older Individuals
ConditionHypothyroidism
Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age65+
SponsorUniversity of Pennsylvania
About this trial
Our overall goal is to determine the clinical consequences of allowing greater flexibility in LT4 dosing in older individuals who take LT4.
Eligibility criteria
Qualifiers
Provision of signed and dated informed consent form
Stated willingness to comply with all study procedures and availability for the duration of the study
Male or female, community dwelling, aged 65 years or older
Diagnosed with hypothyroidism of any etiology for at least 6 months, taking 75-200 mcg per day LT4 and a minimum of 1.2 mcg/kg/day with no dose adjustment since the last TSH test.
Disqualifiers
Hypopituitarism
History of thyroid cancer requiring suppression of TSH secretion
Current use of liothyronine (LT3), thyroid extracts, Tirosint liquid or capsules, and medications that interfere with thyroid function or thyroid function tests
GFR <30 ml/min/1.73 m2 within the prior 12 months
Trial design
Treatments tested in this trial
- Levothyroxine Sodium
Treatment groups
228 Participants
are divided into 2 treatment groupsSponsors and collaborators
University of Pennsylvania
Lead sponsor
National Institute on Aging (NIA)
Collaborator
Source ClinicalTrials.gov